Reuters logo
BRIEF-Can Fite Biopharma submits protocol for phase II trial of CF102
October 13, 2016 / 11:16 AM / a year ago

BRIEF-Can Fite Biopharma submits protocol for phase II trial of CF102

Oct 13 (Reuters) - Can Fite Biopharma Ltd :

* Can Fite Biopharma Ltd - Can-Fite submits protocol for phase ii trial of cf102 in treatment of NAFLD/NASH Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below